Clincosm LogoSign in Get a demo

Seroconversion in COVID-19 Recovered Population

Sponsor
Lahore General Hospital (Other)
Overall Status
Completed
CT.gov ID
NCT04558385
Collaborator
(none)
275
Enrollment
1
Location
9
Actual Duration (Months)
30.7
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

This study investigate the kinetics of IgG responses to both N and S proteins in the subjects who suffered from COVID 19 and then had recovered.

Condition or Disease Intervention/Treatment Phase
  • Diagnostic Test: IgG SARS CoV2

Detailed Description

Coronaviruses (CoVs) are enveloped, single positive-strand RNA viruses belonging to the large subfamily Coronavirinae, which can infect mammals and several other animals.The continued spread of coronavirus disease 2019 (COVID-19) has prompted widespread concern around the world, and the World Health Organization (WHO), on 11 March 2020, declared COVID-19 a pandemic. Studies on severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) showed that virus-specific antibodies were detectable in 80-100% of patients at 2 weeks after symptom onset. Currently, the antibody responses against SARS-CoV-2 remain poorly understood and the clinical utility of serological testing is unclear Little is known about the kinetics, tissue distribution, cross-reactivity and neutralization antibody response in COVID-19 patients .

The seropositivity rate of both IgM and IgG responses after onset and recovery of disease, and in the context of both N protein and S protein has not been clarified. The kinetics of antibody responses in critical cases or ICU patients has not been reported, and no studies have suggested whether antibody response is associated with disease prognosis

Study Design

Study Type:
Observational
Actual Enrollment :
275 participants
Observational Model:
Case-Only
Time Perspective:
Retrospective
Official Title:
Seroconversion in COVID-19 Recovered Population: an Observational Study
Actual Study Start Date :
Jul 1, 2020
Actual Primary Completion Date :
Mar 31, 2021
Actual Study Completion Date :
Mar 31, 2021

Outcome Measures

Primary Outcome Measures

  1. IgG SARS CoV2 [5 months]

    Presence or absence of SARV CoV2 IgG antibodies

Eligibility Criteria

Criteria

Ages Eligible for Study:
N/A and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:

Subjects recovered from COVID 19 confirmed on PCR or clinically

Exclusion Criteria:

subjects who have not been confirmed suffering from COVID 19 by PCR or clinically

Contacts and Locations

Locations

Site City State Country Postal Code
1 Lahore General Hospital Lahore Punjab Pakistan 54500

Sponsors and Collaborators

  • Lahore General Hospital

Investigators

  • Principal Investigator: Amina Asif, MPhilMicro, LahoreGeneralHospital.Lahore

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Amina Asif, Assistant Professor, Lahore General Hospital
ClinicalTrials.gov Identifier:
NCT04558385
Other Study ID Numbers:
  • LGH006
First Posted:
Sep 22, 2020
Last Update Posted:
Apr 1, 2021
Last Verified:
Mar 1, 2021
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:
COVID-19

Study Results

No Results Posted as of Apr 1, 2021